Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Invested Capital (2020 - 2021)

Historic Return on Invested Capital for Celldex Therapeutics (CLDX) over the last 3 years, with Q4 2021 value amounting to 0.16%.

  • Celldex Therapeutics' Return on Invested Capital rose 1200.0% to 0.16% in Q4 2021 from the same period last year, while for Dec 2021 it was 0.16%, marking a year-over-year increase of 1200.0%. This contributed to the annual value of 0.23% for FY2021, which is 1800.0% up from last year.
  • Latest data reveals that Celldex Therapeutics reported Return on Invested Capital of 0.16% as of Q4 2021, which was up 1200.0% from 0.24% recorded in Q3 2021.
  • Celldex Therapeutics' Return on Invested Capital's 5-year high stood at 0.16% during Q4 2021, with a 5-year trough of 1.29% in Q2 2018.
  • For the 3-year period, Celldex Therapeutics' Return on Invested Capital averaged around 0.61%, with its median value being 0.29% (2020).
  • Over the last 5 years, Celldex Therapeutics' Return on Invested Capital had its largest YoY gain of 1200bps in 2021, and its largest YoY loss of -200bps in 2021.
  • Quarter analysis of 3 years shows Celldex Therapeutics' Return on Invested Capital stood at 1.23% in 2018, then soared by 77bps to 0.28% in 2020, then surged by 42bps to 0.16% in 2021.
  • Its Return on Invested Capital was 0.16% in Q4 2021, compared to 0.24% in Q3 2021 and 0.28% in Q4 2020.